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Abstract
Parkinson disease (PD) is a neurodegenerative disorder characterized by a selective loss of 
dopaminergic neurons in the substantia nigra. The earliest biochemical signs of the disease involve 
failure in mitochondrial-endoplasmic reticulum cross talk and lysosomal function, mitochondrial 
electron chain impairment, mitochondrial dynamics alterations, and calcium and iron homeostasis 
abnormalities. These changes are associated with increased mitochondrial reactive oxygen species 
(mROS) and energy deficiency. Recently, it has been reported that, as an attempt to compensate 
for the mitochondrial dysfunction, neurons invoke glycolysis as a low-efficient mode of energy 
production in models of PD. Here, we review how mitochondria orchestrate the maintenance of 
cellular energetic status in PD, with special focus on the switch from oxidative phosphorylation to 
glycolysis, as well as the implication of endoplasmic reticulum and lysosomes in the control of 
bioenergetics.
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1. Introduction
Parkinson’s disease (PD) is a neurodegenerative disorder clinically characterized by motor 
deficits such as tremor, bradykinesia, rigidity and postural instability, eventually 
accompanied by non-motor complications such as dementia [1]. These symptoms are mainly 
associated with loss of dopaminergic neurons (DA) of the substantia nigra (SN). The 
mechanisms underlying DA death have been investigated in many cellular and animal 
models [2–7]. Mitochondrial dysfunction plays a key role in the development of PD [8, 9]. 
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Damage of mitochondrial electron transport chain (ETC) affecting complex I, mutation of 
genes involved in mitochondrial function and defects in the regulation of mitochondrial 
dynamics has been widely reported in PD pathogenesis [10–13]. Being the main energy-
producing organelles of the cell, mitochondria oxidize carbons obtained from carbohydrates 
and fat, producing ATP through the oxidative phosphorylation (OXPHOS) [14, 15]. 
Accordingly, any process impairing mitochondria may lead to metabolic switching aimed to 
compensate for their diminished ability to produce ATP. For instance, switching from 
OXPHOS to glycolysis is a well-known phenomenon in cancer –the Warburg effect [16]. 
Here, we address the notion that, similarly to cancer, PD is a metabolic-like disease. 
Actually, many PD-related genes are also altered in cancer, suggesting common mechanisms 
in both pathologies [17]. Thus, several epidemiological studies have reported an association 
between PD and cancer, although this link is yet controversial. Thus, whilst initially it was 
described an inverse correlation between PD and cancer vulnerability, a recent study reports 
a positive relationship, at least for certain cancer types, including skin, breast and brain 
cancer [18]. This odd association provides a new perspective to a well-known opposing cell 
fate of degeneration and death of post-mitotic neurons, and the uncontrolled division and 
enhanced resistance to death of cancer cells. An example of this is the loss of function of 
parkin (one of the genes altered in both PD and cancer). Thereby, parkin mutations results in 
the deficiency of E3 ligase activity leading to unfolded protein system (UPS) dysfunction 
and cyclin E build up. CDK2/cyclin E phosphorylates the tumour suppressor retinoblastoma 
releasing the transcription factor E2F-1 from inhibition. In mitotic cells E2F-1 up-regulates 
proteins that facilitate cell cycle progression, but in post-mitotic neurons E2F-1 triggers 
apoptosis through p53 and Bax [19, 20].
Mitochondrial dysfunction leading to metabolic shift and, eventually, neuronal death, may 
also be a consequence of decreased ability to clear the damaged mitochondria. This can lead 
to a positive loop of mitochondrial damage, as complex I inhibition, observed in PD and 
some PD experimental models, increases mROS formation that in turn can oxidize 
mitochondrial DNA (mtDNA) and other components of the ETC that contribute to oxidative 
stress [21]. Thus, defects in regulation of mitochondrial dynamics leading to mitochondrial 
dysfunction may also be involved in PD and, although the specific role of mitochondrial 
dynamics in PD pathogenesis remains unknown, both toxin and genetic models of PD show 
signs that interrelate them. Thus, toxins such as MPTP cause Drp1-dependent mitochondrial 
fragmentation and increased mitophagy in SH-SY5Y cells and dopaminergic neurons [22]. 
Rotenone, at high concentrations, induce mitochondrial fission and cell death in primary 
neurons, being this ameliorated by increased fusion or inhibited fission after overexpression 
of Mnf1 or inhibition of Drp1 [23]. In the case of genetic models, α-synuclein 
overexpression inhibits mitochondrial fusion by interaction with mitochondrial membranes 
leading to fragmented mitochondria [24, 25]. Loss of Parkin and Pink1 triggers increased 
vulnerability to mitochondrial damage in cells [10, 27, 28]. Under normal conditions, parkin 
protein is recruited in impaired mitochondria via a Pink1-dependent mechanism to induce 
mitophagy [29]. This process involves ubiquitylation of mitochondrial aberrant proteins for 
proteasomal degradation. Accordingly, the lack of function of Pink1 or Parkin leads to the 
accumulation of misfolded proteins, such as α-synuclein, which is accumulated in the PD 
brain. Furthermore, under normal conditions, PINK1 and Parkin promote fission and inhibit 
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fusion processes, hence the loss of either protein alters mitochondrial morphologies, 
producing Drp1-dependent mitochondrial fragmentation and decreasing the mitochondrial 
membrane potential and ATP production [30, 31]. Loss of DJ-1 in cortical neurons reduces 
fission and increase mitophagy, which is reverted by PINK1 and Parkin [26]. DJ-1is also 
involved in the degradation of misfolded proteins, thus protecting from mitochondrial 
fragmentation after damage; it has been observed that Parkin, Pink1 and DJ-1 form a 
complex having E3 ligase activity [32]. However, many reports have shown that DJ-1 acts in 
parallel to, or up-stream of, the Pink1/Parkin pathway [33, 34]. DJ-1, via its Cys106, may 
also act as a redox sensor protein exerting protection against oxidative stress [35]. Finally, 
LRRK2 also affects mitochondrial function and dynamics. Thus, aged transgenic mutant 
LRRK2 mice exhibit increased damaged mitochondria and mitophagy in cerebral cortex and 
cultured neurons. This may be mediated by Drp1 because LRRK2 interact with Drp1 
enhancing its recruitment into mitochondria. However, this is yet controversial as it depends 
on the cell type, thus further studies still need to be done [36].
The endoplasmic reticulum (ER)-mitochondria crosstalk is critically important to preserve 
mitochondrial and cellular integrity. ER-mitochondria contact sites transfer Ca2+ from ER to 
mitochondria to sustain cell metabolism and bioenergetics [28, 37, 38]. Recent studies 
suggest PD to be linked to other metabolic diseases, such as diabetes or metabolic syndrome 
[39]. For instance, epidemiological evidence links type 2 diabetes mellitus (T2DM) with the 
pathogenesis of PD, since mitochondrial dysfunction and ER-stress leads to insulin 
resistance [40]. Interestingly, DJ-1 activity is reduced in both PD patients and patients with 
T2DM [41]. ER-stress alters protein folding leading to accumulation of α-synuclein to form 
the PD typical Lewy bodies cytoplasmic inclusions [42], as well as reduces insulin secretion 
in diabetes [43]. Inflammation, another key factor risk in PD [44, 45] is also observed in 
T2DM [46]. Insulin receptors are present in the substantia nigra [47] and impaired insulin 
signalling affects glucose uptake in this brain area and causes neuronal dysfunction by 
inactivating KATP channels [48]. High fat diets lead to insulin resistance and accelerate PD 
progression in a rodent model [49]. Lipids and ceramides, generated from saturated fatty 
acids, are antagonists of insulin activity, thus likely connecting insulin resistance with 
neurodegeneration [50]. Cytochrome P450, a typical liver enzyme that is regulated by the 
brain dopaminergic system in rodents, has been found damaged in PD patients [51, 52]. 
Finally, there are similarities in DJ-1 signalling pathways found in brain and pancreas [41].
In summary, there is a large body of evidence suggesting the occurrence of important links 
between glucose homeostasis and PD, being mitochondria a critical nexus. Here, we review 
this novel aspect of neurodegeneration with the aim to contribute shedding light on the 
search for future novel therapeutic strategies.
1.1 Dopaminergic neurons are particularly sensitive to metabolic imbalance
The dopaminergic neurons of the substantia nigra pars compacta (SNpc DA neurons) are 
highly energy demanding, a feature that is likely due to the metabolic sustaining of their 
unusually large axonal arborisation [6, 53]. Interestingly, by reducing the arborisation of the 
SNpc DA neurons using semaphorin-7A, OXPHOS activity and survival are decreased when 
exposed to the parkinsonian-like compounds MPP+ and rotenone [53]. mROS production in 
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the SNpc DA neurons is higher than in other neurons due to the dopamine oxidative 
metabolism, and takes place in the axon terminals, where the mitochondrial density is higher 
than in the ventral dopaminergic neurons [53, 54]. Iron content has been reported to be high 
in the SNpc DA neurons, which may be consequence of its enhanced release from ferritin 
caused by O2•−, from haemoglobin and cytochrome c by peroxides, and/or from iron-sulfur 
proteins by peroxynitrite (ONOO−). Thus, increased of metal ions such as Fe2+ enhance 
H2O2 conversion to •OH via the Fenton reaction, which amplifies oxidative stress [55]. 
Interestingly, iron-mediated oxidative stress can promote α-synuclein aggregation by 
catalysing α-helix conversion into β-sheet, which forms the partially-folded intermediates 
that are susceptible to aggregation [55]. Antioxidants, such as reduced glutathione and 
peroxiredoxin 5, are weakly synthesized in the SNpc DA neurons [55–57]. SNpc DA 
neurons pacemaking is dependent on a particular L-type voltage-dependent Ca2+ channels 
that leads to large Ca2+ influx and subsequent ATP-dependent extrusion, thus increasing 
ATP requirements and oxidative stress [58–61]; in fact, antagonists of this L-type channel 
are neuroprotective [59, 62]. Finally, 1-acetyl-6, 7- dihydroxyl-1, 2, 3, 4-
tetrahydroisoquinoline (ADTIQ), a neurotoxin found in the brain of PD patients, is 
synthesized from a dopamine-derived tetrahydroisoquinoline (TIQ) and methylglyoxal, a 
major side product of glucose metabolism. Thus, glycolytic up-regulation after 
mitochondrial dysfunction, along with increased TIQ synthesis in DA neurons, could 
enhance the synthesis of ADTIQ, thus contributing to DA neuron degeneration [63]. 
Altogether, these observations suggest that the particular metabolism and morphology of 
SNpc DA neurons render them more vulnerable to perturbations of mitochondrial functions 
in response to multiple factors, such as gene mutations, environmental toxins, and aging.
2. Mitochondrial dysfunction, mROS and energetic metabolism in PD
ROS are continuously produced in all tissues, and their production and detoxification are 
tightly balanced. Shifting this balance enables ROS to activate intracellular signalling and/or 
generate oxidative stress, eventually inducing cell death. Oxidative stress is one of the 
hallmarks of PD, being the major sources of ROS the DA neurons [64–66]. Dopamine is an 
unstable molecule able to produce reactive quinones and free radicals by tyrosinase and 
monoamine oxidase (MAO)-catalysed auto-oxidation [67, 68]. Intra-mitochondrial iron 
overloading causes oxidative stress, since ferric and ferrous ions (Fe3+, Fe2+) can react with 
superoxide anion (O2•−) and hydrogen peroxide (H2O2) to generate hydroxyl radicals 
through the Fenton reaction; these ROS synergize with dopamine oxidation to trigger 
neurotoxicity [69, 70]. Hydroxyl radicals generation and decreased glutathione contributes 
to ROS toxicity and neurodegeneration associated with PD [71]. Maintaining Ca2+ 
homeostasis requires ATP-dependent pumps [72], which increase the energy demand and 
OXPHOS activity, consequently leading to higher ROS generation. As above-mentioned, 
SNpc DA neurons express L-type Ca2+ channels for Ca2+ influx, which causes basal 
mitochondrial oxidative stress likely responsible for cell death acceleration [72].
PD is associated with chronic neuroinflammation, a phenomenon controlled by the brain 
microglial cells. Microglial activation has thus been observed in both sporadic and familial 
PD patients [73]. Microglial activation in turn leads to increased cytokine formation, ROS 
production and decreased secretion of trophic factors, inducing neuronal death [66, 74, 75]. 
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Toxins, such as MPTP and rotenone, as well as mutations of PD-associated proteins like α-
synuclein, Parkin, Pink1, DJ-1 and LRRK2, have been reported to activate glial cells and 
release ROS, inducing astrocyte activation thus amplifying the pro-inflammatory response 
and increasing microglial phagocytosis [76–79]. As already indicated, mitochondrial 
dysfunction triggers ROS formation [80]. Complex I and, to a smaller extent, complex III of 
the ETC are considered to be the main sites of mROS production [21]. Complex I inhibition 
results in enhanced ROS production, and excess ROS inhibit complex I. Inhibition of 
complex I activity is well known to occur in the SNpc of PD patients [81–83]. 
Environmental factors, such as MPTP or rotenone, as well as the loss-of-function of PD-
related proteins such as Parkin, Pink1 or DJ-1, are known factors that inhibit complex I 
directly or indirectly, thus disrupting ATP synthesis and increasing ROS [84–88]. 
Interestingly, the alternative electron carrier methylene blue (MB), which accepts electrons 
from NADH and transfers them to cytochrome c thus bypassing complexes I–III, is able to 
increase cellular oxygen consumption and to reduce glycolysis in cultured cells, attenuating 
the toxicity of complex I inhibition by rotenone [89].
When mROS is produced in excess and OXPHOS is impaired, it is often observed a 
compensative enhanced glycolytic activity, thus suggesting that mROS and glycolysis 
interact during cell energy homeostasis [90]. For instance, in skeletal muscle and cultured 
cells, H2O2 stimulates glucose uptake [91–94]. Interestingly, in L6 myoblast, glucose uptake 
inhibition leads to increased ROS [95] and suggests a possible antioxidant-like role for 
glucose. Out of the 14 glucose transporter (GLUT) isoforms described so far [96], GLUT1 is 
up-regulated by ROS [97]. In fact, GLUT1 transcriptional expression is governed by 
transcription factors including hypoxia-inducible factor-1 (HIF-1) [98]. HIF-1 is composed 
by two subunits, α and β, being its activity mainly regulated through the stabilization of its 
α-subunit. Under normoxic conditions, the α-subunit is degraded by the proteasome, which 
requires hydroxylation on the Pro residues present in the O2-dependent degradation domain. 
During hypoxia, hydroxylation is inhibited hence HIF-1α is stabilized, enabling the 
formation of a complex with HIF1β that is translocated into the nucleus to promote the 
expression of several genes, including those encoding GLUT1 and enzymes of the glycolytic 
pathway [87, 99]. Interestingly, mROS also stabilize HIF1α [87]. In muscle, GLUT1 
activity is increased by 5′-AMP-activated protein kinase (AMPK) [100], a protein kinase 
that is activated by LKB1-mediated phosphorylation during elevated AMP/ATP ratio or 
mROS [101–103]. Both HIF1 and AMPK activation leading to increased glucose uptake has 
been observed in PD models [87, 104]. GLUT1 activity can also be increased by 
translocation to the plasma membrane, which takes place through a ROS-mediated oxidation 
of key sulfhydryls in the Ataxia Telangiectasia Mutated (ATM) protein forming an active 
dimer [105, 106]. ATM is localized close to the mitochondria, suggesting that its 
dimerization is mediated by mROS [107].
Glucose metabolism can play a role in regulating the ROS production and scavenging 
balance. For instance, glucose oxidation through the pentose phosphate pathway (PPP) 
produces reducing equivalents in the form of NADPH, which is necessary to recycle 
antioxidant glutathione from its oxidised status [108]. This is especially important in 
neurons because they are more vulnerable to oxidative stress than other cell types. In 
neurons, the limiting glycolytic enzyme 6-phosphofructo-2-kinase/fructose-2,6-
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bisphosphatase-3 (PFKFB3) is continuously degraded by the proteasome, and this is why 
they preferentially metabolize glucose via the PPP instead glycolysis, in contrast to what 
happens with other cells with more robust antioxidant system [109]. Thus, inhibiting glucose 
flux through the PPP increased levels of oxidative stress and neuronal death [109]. In 
addition, certain stimuli are able to stabilize PFKFB3, switching from PPP to glycolysis 
[110]. This leads to increased oxidative stress and apoptotic neuronal death that counteract 
with overexpression of glucose-6-phosphate dehydrogenase, the rate-limiting enzyme of the 
PPP. Both increased glycolysis and decreased PPP were shown to be abolished by siPFKFB3 
indicating that both metabolic pathways are fully controlled by this protein [110]. Thus, 
proteasome dysfunction during the loss of Parkin or other PD-related proteins would likely 
stabilize PFKFB3 leading to a switch from PPP to glycolysis and oxidative stress. 
Interestingly, a down-regulation of PPP rate-limiting enzymes has been documented in post-
mortem brain samples of PD patients [111], strongly supporting the hypothesis that PPP 
disruption may be an important factor in the pathogenesis of PD [111, 112] and aging [112].
3. Implications of mitochondrial quality control for metabolism in PD
Failure in the mitochondrial quality control mechanisms impairs the mitochondrial ability to 
generate energy by OXPHOS, which can invoke glycolysis as an attempt to maintain cellular 
ATP (Fig. 1). Mitochondrial quality control mechanisms require communication between 
mitochondria and other organelles, including the ER and lysosomes, as disruption of this 
process has been observed in PD and other neurodegenerative disorders such as Gaucher 
disease (GD) [113].
3.1 Mitochondria-lysosome crosstalk
Mitochondrial dysfunction in neurodegenerative diseases involves alterations in the 
mitochondrial quality control mechanisms [114–116]. Mitochondrial turnover mainly occurs 
by autophagy, a process requiring functional lysosomes. Lysosomes are critical for protein 
and organelles degradation [117], calcium signalling [118, 119], endocytic processes [120], 
and nutrient sensing [121]. During autophagy, lysosomes fuse with autophagosomes to 
promote degradation of engulfed organelles and proteins. The membrane origin of 
autophagosome remains unclear; some studies suggest that they are generated “de novo”, 
whereas other studies suggest that they arise from other organelles such as ER or 
mitochondria [122]. The process is initiated by activation of Vps34 and its interaction with 
Beclin-1. This is produced only if the anti-apoptotic protein Bcl2 is phosphorylated and 
dissociated from Beclin-1, indicating a link between autophagy and apoptosis [122]. After 
maturation, autophagosome fuses with the lysosome to form the autophagolysosome, in 
which organelles and/or misfolded proteins are degraded and recycled. Thus, failure in these 
processes may lead to the accumulation of aberrant mitochondria and misfolded proteins, 
which are hallmarks of PD. In addition, mutations in genes encoding lysosomal proteins 
cause lysosomal storage diseases (LSDs), which are accompanied by the accumulation of 
damaged mitochondria. Actually, failure in lysosomal function seems to be an event 
occurring earlier than mitochondrial damage [123]. Amongst other substrates, α-synuclein is 
aggregated [124]. Mutant α-synuclein tightly binds to the lysosomal membrane to inhibit the 
autophagy-lysosome pathway, resulting in degradation of wild type α-synuclein [116]. 
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Besides PD, α-synuclein aggregates are also observed in GD, the most common of the LSDs 
caused by recessive mutations in glucocerebrosidase (GBA). Thus, GD and PD have similar 
hallmarks including loss of DA neurons of SNpc, α-synuclein accumulation, tremor, 
bradykinesia and rigidity. In addition, mitochondrial membrane potential (Δψm) collapse 
and mitochondrial complex I-derived ROS-mediated ETC damage also occur [113, 122].
3.2 ER-mitochondria tethering
Mitochondria and ER are tightly interconnected, both physically and functionally. ER-
mitochondria contact sites, known as mitochondria-associated membranes (MAMs) [125], 
facilitate Ca2+ and lipid transfer between these organelles, acting as platforms for signals 
regulating cell death and survival mechanisms [126–129]. Mitochondrial Ca2+ levels 
regulate ATP synthesis by activating tricarboxylic acid (TCA) dehydrogenases [130] and 
ATP synthase [131, 132]. However, mitochondrial Ca2+ also triggers apoptotic cell death 
[133, 134] through mechanisms that take place at the ER-mitochondria interface. Disruption 
of normal ER function leads to misfolded and unfolded protein accumulation in the ER, a 
process known as the unfolded protein response (UPR) that is an adaptive cellular response 
to ER stress aimed to restore ER homeostasis [135]. Interestingly, UPR includes changes in 
metabolism focused to provide metabolic support for the cellular adaptation. Thus, the 
increase in ER-mitochondrial contact sites leads to an increase in mitochondrial Ca2+ 
uptake, mitochondrial metabolism and ATP production [136]. On the contrary, disruption of 
ER-mitochondrial contacts, or blockage of Ca2+ transfer, increases cell death in response to 
ER stress [135, 136]. Thus, although ER-mitochondria contacts are beneficial in early stages 
of ER stress, these contacts lead to cell death if stress is maintained for long periods of time 
by Ca2+ overloading.
ER-mitochondrial contact sites are important for cell signalling. Thus, MAM are involved in 
insulin signalling [137], as several components of the insulin cascade, such as Akt and 
mTORC2, have been found at the MAM [137–139]. Inhibition of mitochondrial Ca2+ 
uptake, in skeletal muscle cells and cardiomyocytes, reduces insulin-dependent Akt 
phosphorylation, GLUT4 membrane translocation, and glucose uptake [140, 141]. Obesity 
in mice is accompanied by an increase in MAM and Ca2+ overloading, suggesting a 
pathophysiological role of MAM in insulin resistance and T2DM [142]. MAM disruption 
may also be involved in neurodegeneration, particularly in PD, since Parkin, Pink1, DJ-1 and 
α-synuclein are present in the ER-mitochondrial contact sites to support Ca2+ transfer. For 
instance, α-synuclein mutations decrease the number of ER-mitochondria contact sites, 
causing ER stress and mitochondrial fragmentation [37]. Thus, ER-mitochondria tethering is 
disrupted in both T2DM and PD, further suggesting a link between these disorders.
4. Metabolic disturbances in sporadic models of PD
As above mentioned, mitochondrial complex I damage has been shown in post-mortem 
brains, skeletal muscle, platelets and lymphocytes of PD patients [81, 143–147]. Inhibitors 
of complex I activity, such as methyl-4-phenylpyridinium (MPP+) and rotenone induce 
mitochondrial dysfunction in dopaminergic cells [148]. Likewise, 6-hydroxydopamine (6-
OHDA) is used as a dopamine analogue to induce ROS-associated degeneration of SNpc DA 
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neurons [149]. Since MPP+, rotenone and 6-OHDA are widely used to model the 
dopaminergic neuronal death of PD, both in cultured cells and in experimental animals, we 
revisit the metabolic disturbances found in several chemical models of PD.
4.1 MPP+
MPP+, the bioactive metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), 
causes a clinical picture similar to PD syndrome in humans and non-human primates, being 
widely used to investigate therapeutic strategies [150, 151]. Thus, MPTP is metabolized in 
the brain in astrocytes, by monoamine oxidase-B, to MPP+, which is released to the 
extracellular space and taken up by dopaminergic neurons through the dopamine transporter 
(DAT) [152]. MPP+ is accumulated in mitochondria where it inhibits complex I [151, 153, 
154]. Consequently, OXPHOS is blocked and neurons become dependent on glycolysis for 
ATP production. Thus, by increasing the rate of glycolysis, neurons could compensate for 
the mitochondrial deficiency in ATP synthesis and hence to meet the cell energy demands 
[155, 156]. In fact, it has been found that maintaining cell ATP concentrations via glycolysis 
attenuates MPP+-induced toxicity [157]. On the contrary, a glucose-deficient environment 
exacerbates MPP+-induced toxicity [158]. Studies in neuroblastoma cells and in rat brain 
indicate that glucose prevent MPP+ toxicity by attenuating ATP depletion without recovering 
mitochondrial respiration, hence indicating increased glycolysis [159, 160]. Interestingly, at 
MPP+ concentrations below 1 mM, its toxicity depends of glucose depletion; however, at 
MPP+ concentrations between 1 and 10 mM, cells undergo a metabolic collapse with a 
switch from OXPHOS to glycolysis that leads to cell death [159]. Thus, the mechanism of 
MPP+ toxicity is biphasic, namely (i) the DAT-mediated mechanism selective for 
dopaminergic neurons (at low concentrations) and (ii) the oxidative mechanism that occur a 
higher concentrations [160]. In SH-SY5Y and differentiated human neural progenitor 
ReNcell VM cells, microRNA-7 increases the neuronal expression of GLUT3 through 
targeted repression of RelA, which promotes glycolysis as evidenced by increased glucose 
consumption and lactate release, increased ATP and prevention against low dose MPP+-
induced cell death [161].
4.2 Rotenone
Rotenone, initially used as an insecticide and fish poison, increased PD incidence in farming 
communities exposed to this compound [162]. Rotenone crosses the blood brain barrier and 
plasma membranes due to its hydrophobicity. DA neurons are particularly susceptible to 
rotenone-induced degeneration [163]. In vitro and in vivo exposure to rotenone induces both 
soluble and insoluble α-synuclein aggregates, increased caspase activation and apoptosis 
[164–166]. Inhibition of complex I and cellular respiration by rotenone results in the 
compensatory induction of glycolysis, loss of bioenergetics reserve capacity, activation of 
apoptotic pathways, and cell death [167]. Rotenone decreases maximal respiration and 
reserve capacity at doses that MPP+ increases this reserve capacity, indicating that both 
compounds act a different level of the ETC; while rotenone inhibits complex I, MPP+ 
inhibits both complex I and ATP synthase or related [167]. However, rotenone shows a 
mechanism of action other than solely ETC disruption leading to ROS production [168], 
since it induces glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression and 
nuclear and mitochondrial translocation. Accumulated GAPDH promotes intermolecular 
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disulphide bonding resulting in the formation of intracytoplasmic aggregates of GAPDH, 
which may contribute to the formation of inclusion bodies, such as Lewy bodies, and 
neuronal apoptotic death [169].
4.3 6-Hydroxydopamine (6-OHDA)
6-OHDA, the hydroxylated analogue of dopamine, has been found in human brain and urine 
from PD patients treated with L-dopa [170, 171]. 6-OHDA reversibly inhibits the activities 
of complexes I and IV in rat brain mitochondria [172], although it also induces degeneration 
of SNpc neurons by oxidative damage via auto-oxidation, which forms reactive quinones 
that generate hydrogen peroxide and superoxide [173]. 6-OHDA reacts with Fe3+ causing its 
release and subsequent cellular damage [174]. This is particularly relevant for PD 
pathogenesis since SNpc DA neurons contain higher iron levels associated to neuromelanin 
[175, 176]. Differentiated SH-SY5Y treated with 6-OHDA do not show, however, OXPHOS 
inhibition, thus 6-OHDA likely impacts on mitochondrial redox signalling rather than on 
bioenergetics [167]. However, the oxidative stress produced by 6-OHDA indirectly causes 
mitochondrial dysfunction, which leads to glycolysis up-regulation [177].
4.4 Paraquat
The herbicide paraquat (1,1′-dimethyl-4,4′-bipyridinium dichloride) is structurally similar 
to MPTP, and it has been associated with PD [162, 178]. Paraquat causes selective and-dose 
dependent loss of SNpc DA neurons [179, 180]. It is unlikely that paraquat inhibits complex 
I, but it produce ROS [181] both in vitro and in vivo by multiple mechanisms, including 
redox cycling [182, 183] and nitric oxide synthase activity [184]. Thus, the mechanism 
whereby paraquat exerts neurotoxicity is different from those used by MPP+, rotenone or 6-
OHDA [177]. Using a combined metabolomics approach by nuclear magnetic resonance 
(NMR) and direct-infusion electrospray ionization mass spectrometry (DI-ESI-MS), it has 
been revealed that human dopaminergic neuroblastoma cells exposed to paraquat presented 
deeper alteration in PPP metabolome. Thus, metabolites of PPP such as glucose-6-
phosphate, fructose-6-phosphate, glucono-1,5-lactone, and erythrose-4-phosphate have been 
found increased after paraquat treatment, an effect that was accompanied by inhibition of 
glycolysis and TCA cycle activity. In addition, increased expression of glucose-6-phosphate 
dehydrogenase (G6PD), which supplies NADPH, was observed with paraquat. These 
findings have led to the proposal that increased PPP, by enhancing NADPH levels, would be 
necessary for paraquat redox cycling causing oxidative stress [177].
5. Metabolic disturbances in genetic models of PD
During the last two decades, several genetic mutations have been found to be associated with 
familial forms of PD with similar clinical and pathological features of those in idiopathic PD 
[185–187]. The study of the proteins encoded by these genes has revealed the close link with 
mitochondrial function and metabolism, thus providing important insight about the 
molecular pathways and mechanism that may underlie neurodegeneration in PD.
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5.1 α-synuclein
Mutations such as A530T, A30P and E46K, as well as duplication or triplication of the α-
synuclein gene (PARK1, SNCA) have been associated with autosomal dominant PD [188–
191]. α-synuclein is a hydrophobic protein prone form the typical fibrillar aggregations 
observed in Lewy bodies, which links this protein with both sporadic and familial forms of 
PD [42]. α-synuclein aggregation inhibits mitochondrial complex I activity, elevates ROS 
production [192] and increases protein-carbonyl levels [193]. In vitro, the interaction of α-
synuclein with mitochondria leads to cytochrome c release, enhances mitochondrial Ca2+, 
and triggers oxidative modifications of mitochondrial components [194]. These findings 
suggest an interrelation between protein aggregation and mitochondrial dysfunction, 
granting to α-synuclein a role as a modulator of oxidative stress. α-synuclein increases with 
ageing along with a loss of tyrosine hydroxylase-positive neurons [195, 196]. The 
accumulation of unfolded/misfolded α-synuclein leads to ER stress, which activates UPR 
[197] and correlates with markers of the UPR pathways protein kinase RNA-like ER kinase 
(PERK) and activating transcription factor-6 (ATF6), as well as its downstream pro-
apoptotic CCAAT/-enhancer-binding protein homologous protein (CHOP) [197]. 
Overexpression of the ER chaperone, glucose regulated protein 78 (GRP78/BiP), decreases 
α-synuclein toxicity by down-regulating ER stress mediators [197]. Such an ER stress 
response reprograming prevents DA neurons death, reinforcing the key role of ER in PD 
neurodegeneration. In addition, α-synuclein is also present in MAM [37], hence connecting 
ER and mitochondria to regulate Ca2+ homeostasis and cholesterol metabolism [125, 127, 
198]. Mutated α-synuclein reduces its association with MAM concomitantly with a decrease 
in ER-mitochondria juxtaposition and increased mitochondrial fragmentation. 
Overexpression of the mitochondrial fusion protein MFN2 or inhibition of the mitochondrial 
fission protein Drp1 do not revert such phenotype, indicating that α-synuclein acts 
downstream of the mitochondrial fusion/fission machinery [37].
Besides the above-mentioned functions linked to mitochondrial dysfunction, α-synuclein 
directly alters carbohydrate and lipid metabolism. Using a mouse model of PD that express 
the mutant form of human α-synuclein A53T, it has been observed that a high caloric diet 
induces a metabolic phenotype similar to that of the PD patients; this consists of a reduction 
of total and visceral body fat, hypoleptinemia, and increased energy expenditure without 
insulin resistance [199]. α-synuclein, which is present in pancreatic β-cells, down-regulates 
insulin secretion by interacting with KATP channels; however, if over-expressed, or 
expression of the mutant α-synuclein, results in excessive inhibition of insulin secretion 
contributing to diabetes, generating cellular stress and apoptosis resembling PD [200]. In 
contrast, α-synuclein ablation exacerbates insulin resistance in mouse adipose tissue and 
skeletal muscle, as well as in patients with low α-synuclein blood levels and increased 
insulin resistance [201]. In the adipose tissue and skeletal muscle of α-synuclein knockout 
mice, it has also been observed an increase in GLUT4-driven glucose uptake through an 
insulin-independent mechanism [202].
5.2 Parkin
Mutations in Parkin (PARK2) gene produce autosomal-recessive juvenile PD [203, 204]. As 
an E3 ubiquitin ligase involved in the proteasomal degradation of several substrates, loss of 
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Parkin causes accumulation of potentially toxic protein aggregates eventually involved in PD 
pathogenesis [205]. Parkin is confined to mitochondria, where it binds transcription factors 
such as the mitochondrial transcription factor TFAM [206]. Parkin prevents cytochrome c 
release [207] and α-synuclein aggregation, thus protecting mitochondria and attenuating DA 
neuronal loss [208]. In contrast, loss of Parkin impairs complex I and IV activities both in 
humans and mice, leading to mitochondrial respiration impairment and oxidative stress [86, 
209]. Parkin loss also increases toxins sensitivity [210, 211] and disturbs mitochondrial 
dynamics and autophagy [29, 212]. Thus, Parkin participates in mitochondrial fission and 
fusion processes, mitochondrial transport, and removal of damaged mitochondria through 
mitophagy via a mechanism dependent on Drp1 [29, 213–215]. The triggering mechanism 
of Parkin-dependent mitophagy is the loss of mitochondrial membrane potential (Δψm), 
which activates its recruitment to the mitochondria through PINK1 (see section below).
Parkin mRNA and protein levels increase during ER stress via the UPR pathway 
transcription factor ATF4, which binds the CREB/ATF elements in the Parkin promoter to 
increase its expression, thus preventing ER stress-induced mitochondrial damage and cell 
death [216]. In HeLa and neuroblastoma cells, Parkin favours ER-mitochondria contacts and 
the transfer of Ca2+ from ER to mitochondria, thus activating ATP synthesis [217]. Parkin 
has also a role in fat uptake [218]. Parkin knockout mice display lower weight gain 
preceding the mitochondrial and neurological abnormalities, which is more evident under a 
high-fat diet [86, 218]. Thus, a high fat diet to wild type mice induces Parkin levels in 
several tissues favouring fat uptake via mono-ubiquitylation, leading to stabilization, of the 
CD36 fatty acid translocase [218]. These results suggest that diet would be an interesting 
factor to consider for delaying the onset, or reduce the risk, of PD.
Parkin is a target of p53 and a potential tumour suppressor [219]. Thus, p53 induces Parkin 
gene transcription, in humans and mice, to mediate the p53 effects on glucose metabolism 
and antioxidant defence. Accordingly, loss of Parkin increases glucose uptake, glycolysis 
and lactate production, and reduces mitochondrial respiration. In addition, Parkin loss down-
regulates the expression of several mitochondrial proteins, such as pyruvate dehydrogenase 
(PDHA1), which catalyses pyruvate conversion to acetyl-CoA in the mitochondria. This 
triggers a Warburg effect that can be restored by over-expressing Parkin [219]. Such a 
Warburg effect has also been linked with other functions of Parkin, such as mitophagy [220], 
mitochondrial dynamics [221] and genome integrity [222]. It should be mentioned that the 
regulation between Parkin and p53 differs depending on the cell line or tissue [219]. 
Nevertheless, it seems well established that loss of Parkin induces a Warburg effect 
contributing to the development of tumours by facilitating cell proliferation [223–225].
5.3 PINK1
PINK1 (PTEN-induced putative kinase; PARK6) mutations are, after Parkin, the second 
most common cause of early onset autosome recessive PD [226]. PINK1 is a serine/
threonine kinase that is stabilized upon Δψm collapse into the mitochondria [227], where it 
recruits Parkin from the cytosol [10, 29]. PINK1 knockdown in human dopaminergic 
neurons and mouse primary neurons causes morphological changes in mitochondria, 
decreased Δψm, high ROS production and apoptosis [228, 229]. Whilst loss of PINK1 in 
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mice decreases complex I and IV activities and impairs mitochondrial respiration, it can also 
exacerbate mitochondrial respiration when exposed to H2O2 or mild heat shock [230]. 
PINK1 prevents cytochrome c release from mitochondria and apoptotic neuronal death [231, 
232], and protects against MPTP-mediated oxidative stress [233].
PINK1 controls mitochondrial dynamics, hence being essential in energy metabolism 
maintenance, mitochondrial quality control, and cell viability [234, 235]. PINK1 promotes 
mitochondrial fission by inducing Drp1, and inhibits mitochondrial fusion by down-
regulating mitofusins (MFN1 and MFN2) [214, 221, 236]. Parkin recruitment by PINK1 
participates in the mitochondrial quality control process by triggering mitophagy [29, 212, 
220]. A subpopulation of mitochondrial-derived vesicles (MDVs) requires Parkin and 
PINK1 to be formed. MDVs mediate the transport of mitochondria to lysosomes for the 
degradation of oxidized cargo proteins, thus regulate mitochondrial quality control under 
mild stress; however, failure of this protective system causes irreversible mitochondrial 
damage leading to mitophagy [237].
As most PD-related proteins, Parkin and PINK1 are present in MAM. PINK1 is involved in 
the regulation of ER-mitochondria Ca2+ transfer by increasing ER-mitochondrial contact 
sites [238]. As above-mentioned, Ca2+ transfer is essential for mitochondrial respiration and 
normal cell bioenergetics. In PINK1 deficient cells, Ca2+ homeostasis is a controversial 
matter. In neurons, PINK1 regulates Ca2+ efflux from mitochondria through Na+/Ca2+ 
exchanger, and PINK1 loss results in Ca2+ overload, inhibition of glucose transporter, and 
respiration impairment [239]. However, other studies report impaired respiration and 
increased glycolytic activity in myocytes and neurons from PINK1 knockout mice [239]. 
Glucose uptake is impaired in PINK1-deficient pancreatic β-cells, which produce an 
increase in intracellular Ca2+ and insulin secretion under low glucose conditions resulting in 
glucose tolerance in vivo [240]. Myocytes, which have higher ATP producing capacity and 
Δψm, can buffer cytosolic Ca2+ rendering these cells resistant to Ca2+ stress [241]. 
Knockout and knockdown mouse neuroblastoma and embryonic fibroblasts (MEFs) for 
PINK1 showed reduced mitochondrial Ca2+ uptake and impaired mitochondrial ATP 
synthesis, leading to Ca2+ efflux [28]. In other studies performed in MEFs and primary 
cultured neurons from PINK1 knockout mice, mitochondrial deficiency leads to increased 
glycolysis with lactate release, along with increased glucose uptake leading to a Warburg-
like effect through HIF1α stabilization [87, 242].
PINK1 was identified originally because of its tumour suppressor action [243]. However, 
whether loss of PINK1 represses or enhances cell proliferation is yet controversial. Thus, 
PINK1 is induced by the tumour suppressors PTEN and FOXO3a, and it is associated with 
Beclin-1, which is a tumour suppressor [243–245]. In addition, PINK1 acts upstream of 
Parkin, which is a tumour suppressor through interaction with p53 [219]. Furthermore, 
PINK1 gene is located in a region of chromosome 1p36 that contains tumour-suppressive 
activity [246]. In contrast, PINK1 is necessary for optimal activation of the oncogenic 
pathway IGF1/Akt, which indicates pro-oncogenic functions [247]. As indicated above, 
PINK1 is essential for mitochondrial dynamics, Ca2+ homeostasis and mitophagy, which are 
processes related to the cell cycle regulation [248–252]. MEFs isolated from PINK1 
knockout mice show altered cell cycle, with cells multinucleated arrested in G2/M phase and 
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a decreased number of cells in G0/G1 [253]. This leads to a reduction in cell proliferation 
and an increase in mitochondrial fission according to the high levels of Drp1 observed [253]. 
However, in another study using identical PINK1 knockout cells, the opposite result was 
found, i.e., the proportion of cells in G2/M phase increased and the proportion of cells in the 
G0/G1 phase decreased, leading to enhanced cell proliferation rate concomitant with a 
higher glycolytic rate [87]. In this study, the rate of glycolysis was found to be essential for 
cell proliferation, since the inhibitor 2-deoxyglucose abrogated it. Moreover, the increase in 
the glycolytic rate was mediated by HIF1α, as silencing of this transcription factor reverted 
both the increase in glycolysis and in cell proliferation [87]. Interestingly, in this study 
PINK1 knockout mice primary neurons were also used, in which it was observed a shift 
from PPP to glycolysis that led to apoptosis [87]. Thus, PINK1 loss of function may have 
dual consequences, cell proliferation or apoptosis, depending on the cell type and the 
environmental factors. Thus, whilst the cell cycle effects of PINK1 deficiency may be 
responsible for cancer, it may also be involved in neurodegeneration, since the abortive cell 
cycle re-entry is mechanistically linked to the death of post-mitotic neurons [254–257].
5.4 DJ-1
Mutations in DJ-1 (PARK7) gene causes autosomal recessive early onset parkinsonism 
[258]. DJ-1 is a multifunctional protein that under basal conditions is mainly localized in the 
cytosol. However, upon oxidative stress, DJ-1 translocates to the mitochondria and later to 
the nucleus to exert its neuroprotective function [259–261]. Nuclear translocation of DJ-1 
occurs by oxidation of the Cys106 that acts as a redox sensor [259, 262]. Neurons and MEF 
defective in DJ-1 show decreased complex I activity and mitochondrial respiration [88, 263], 
along with increased oxidative stress accompanied by enhanced glycolysis [33]. MEF 
knockout for DJ1 show decreased Δψm and increased mitochondrial permeability transition 
pore [264]. In neurons, DJ-1 knockdown causes ER stress, inhibition of the proteasome, and 
increased cell death [265, 266]. Cell models from human and mouse knockouts for DJ-1 
show altered mitochondrial morphology and accumulation of defective mitochondria [267]. 
In addition, DJ-1-deficient mice show SNpc DA neuronal loss, elevated DA levels and 
enhanced DA re-uptake [268]. In these cells, DJ-1 loss sensitizes them against toxins such as 
MPTP and paraquat, while its overexpression protects them [269, 270]. All these effects can 
be reversed either by over-expressing DJ-1 or by antioxidant treatment, suggesting a key role 
for DJ-1 in antioxidant signalling. On the other hand, DJ-1 fosters the communication 
between RE and mitochondria [238], hence reducing DJ-1 levels causes mitochondrial 
fragmentation and decreased mitochondrial Ca2+ uptake. In HeLa cells, overexpression of 
p53 impairs the transfer of Ca2+ from ER to mitochondria increasing mitochondrial 
fragmentation; this was reversed by DJ-1 overexpression rescuing the ER-mitochondria 
contact sites, but not by Drp1 inhibition, indicating that mitochondrial fragmentation was 
independent of Drp1 activation [38]. Thus, besides its antioxidant role, DJ-1 participates in 
the maintenance of mitochondria integrity by improving ER-mitochondria communication.
DJ-1 is involved in glucose homeostasis. Thus, DJ-1 expression can be regulated under 
hyperglycemic conditions in vitro and in vivo [271, 272]. DJ-1 expression is increased under 
non-diabetic conditions in human and mouse islets during aging to prevent oxidative stress 
and to maintain the mitochondrial integrity that is necessary for glucose-stimulated insulin 
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secretion. Interestingly, decreased DJ-1 expression is observed in PD patients and in patients 
suffering from T2DM, indicating the interrelation between these diseases [41]. In addition, 
DJ-1 has been shown to transcriptionally co-activate PINK1 expression by binding to 
FOXOa3; accordingly, DJ-1 loss causes decreased complex I activity and increased 
glycolysis via regulating PINK1 [33]. Similar effects on glucose metabolism take place in 
DJ-1 knockout mouse skeletal muscle, where a higher energy expenditure, AMPK 
activation, and uncoupled mitochondrial respiration has been observed leading to a Warburg-
like metabolic reprogramming [273]. In good agreement with the view that the Warburg 
effect may favour cell proliferation, loss of DJ-1 increases cell proliferation via regulating 
PINK1 [33].
5.5 LRRK2
Mutations in the leucine-rich repeat kinase 2 gene (LRRK2) are the most common genetic 
cause of PD and cause both autosomal dominant and sporadic PD [274, 275]. Several 
LRRK2 mutations showing gain-of-function cause apoptotic neuronal death that can be 
attenuated by inhibition of mitochondrial-dependent caspases, suggesting mitochondrial 
dysfunction in LRRK2-mediated pathogenesis [276]. In cortical neurons, LRRK2 mutations 
increase ROS and impair mitochondrial morphology and dynamics [277]. LRRK2 interacts 
with Dynamin like protein 1 (DLP1) in neurons, and expression of LRRK2 leads to 
translocation of DLP1 from the cytosol to the mitochondria, suggesting a functional role of 
LRRK2 in mitochondrial dynamics [277]. Mitochondrial elongation and interconnectivity 
are also altered in patients with LRRK2 G2019S mutation, indicating that LRRK2 is related 
to mitochondrial morphology maintenance. Skin biopsies obtained from this LRRK2 mutant 
PD patients also showed Δψm collapse and ATP depletion [278]. These findings, together 
with the fact that LRRK2 is located in mitochondria [279, 280], suggest that mutant LRRK2 
toxicity is linked to mitochondrial damage. Interestingly, the G2019S LRRK2 knock-in 
mouse shows transcriptional down-regulation of OXPHOS genes and up-regulation of 
glycolytic genes; furthermore, this mutant mouse down-regulates ubiquitylation and 
trafficking of proteins, suggesting that the accumulation of aberrant proteins and ER failure 
may underlie the OXPHOS-glycolysis shift [281].
5.6 Other relevant genetic mutations
Genome-wide association (GWAs) studies have revealed the occurrence of novel PD 
relevant loci [282]. For instance, ATP13A2 encodes a lysosomal transmembrane protein that 
belongs to the 5P-type ATPase subfamily [283], the mutations of which are associated with 
PD. ATP32A2 inhibition impairs the lysosomal ability to degrade certain proteins, including 
α-synuclein, by the autophagosome [284, 285]. Furthermore, mutant ATP13A2 causes Δψm 
collapse, ATP depletion, reduced mitophagy, and increased ROS, which can contribute to 
neurodegeneration [286–288]. Similar biochemical signs have been found with the mutant 
PLAG6, another PD-related protein with calcium-independent phospholipase A2 activity 
[289]. Finally, GIGYF2 loss of function causes neurodegeneration linked to insulin 
signalling impairment [290].
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6. Conclusions and perspectives
PD is a complex pathology with both genetic and environmental components. Regardless its 
specific cause, mitochondrial redox and energetic failure are essential pathogenic 
mechanisms in which an intact mitochondrial communication with ER and lysosomes are 
important. Failure in this communication increases misfolded proteins and impairs Ca2+ 
transfer, which accelerates dopaminergic cell death by defective mitochondria accumulation. 
Increased ROS, a key hallmark of this disorder, is linked to a metabolic OXPHOS-glycolysis 
shift aimed to maintain ATP, minimize mROS production and prevent apoptotic death. 
Mutant genes, such as α-synuclein, Parkin, PINK1 or DJ-1, cause excess mROS that are 
relevant for the SNpc DA neurons, which show a particularly high oxidative metabolism. 
Importantly, prolonged oxidative stress can trigger irreversible damage to mitochondria 
leading to a bioenergetics failure that cannot be compensated by increased glycolysis (Fig. 
1). Since under normal conditions glucose utilization via the PPP is an essential antioxidant 
mechanism for neurons, an increased glycolysis aggravates neuronal oxidative stress in PD. 
In addition, the OXPHOS-glycolytic shift facilitates cell proliferation, which may explain 
the link between PD and some tumour development, but also neurodegeneration due to a 
possible aberrant cell cycle re-entry of post-mitotic neurons. Finally, besides the nervous 
system, other tissues affected in PD, such as the liver and pancreas, show important 
metabolic alterations including those related with insulin secretion and impaired glucose 
uptake, which may link diet habits with T2DM in PD. Thus, loss of the mitochondrial 
control of bioenergetics appears to be behind the causes of this metabolic syndrome-like 
picture in PD. This may provide clues when designing novel future therapeutic strategies 
against PD.
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6-OHDA 6-hydroxydopamine
ADTIQ 1-acetyl-6, 7- dihydroxyl-1, 2, 3, 4-tetrahydroisoquinoline
AMPK 5′-AMP-activated protein kinase
ATF activating transcription factor 6
ATM ataxia telangiectasia mutated
CHOP CCAAT/-enhancer-binding protein homologous protein
DA dopamine
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PFKFB3 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3
G6PD glucose-6-phosphate dehydrogenase
GAPDH glyceraldehyde-3-phosphate dehydrogenase
GBA glucocerebrosidase
GD Gaucher disease
GLUT glucose transporter
GRP78/BiP glucose regulated protein 78
HIF-1 hypoxia inducible factor 1
LSDs lysosomal storage diseases
MAMs mitochondrial-associated membranes
MB methylene blue
MDVs mitochondrial-derived vesicles
MPP+ methyl-4-phenylpyridinium
MPTP 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
Paraquat 1,1′-dimethyl-4,4′-bipyridinium dichloride
PD Parkinson’s disease
PDHA pyruvate dehydrogenase
PERK protein kinase RNA-like ER kinase
PINK1 PTEN-induced putative kinase 1
PPP pentose phosphate pathway
SN substantia nigra
SNCA α-synuclein gene
T2DM type 2 diabetes mellitus
TIQ tetrahydroisoquinoline
UPR unfolded protein response
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Highlights
• Neuronal management of energetic status in Parkinson’s Disease (PD) 
is reviewed
• Mitochondria, endoplasmic reticulum and lysosomes involvement in 
PD are discussed
• Mitochondrial dysfunction leads to neuronal metabolic re-
programming in PD
• Increased neuronal glycolysis shifts down pentose-phosphate pathway 
(PPP) in PD
• Down-regulation of PPP in neurons may account for PD-associated 
oxidative stress
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Figure 1. Cellular pathways associated with bioenergetics in PD
Genetic mutations in PD-related genes and/or exposure to environmental toxins lead to an 
increased oxidative stress and mitochondrial failure that affect several metabolic pathways. 
Dysfunctional mitochondria induce the aggregation of proteins, such as α-synuclein, due to 
impairment in the ubiquitin/proteasome and autophagy/lysosome pathways. This also leads 
to alterations in the cross-talk between mitochondria and ER, contributing to increased 
mROS. Additional factors, such as dopamine metabolism or glial activation may also 
contribute to increased ROS. Excessive ROS interfere with ATP synthesis and contribute to 
the stabilization of proteins, such as HIF-1, which mediates glycolytic up-regulation in order 
to compensate for the mitochondrial energy impairment. However, increased glycolysis may 
have adverse effects in neurons. Thus, glycolysis facilitates a failed attempt of post-mitotic 
cells to re-enter the cell cycle, a feature that may be important in genetic PD-related 
mutations affecting p53. Also, certain glycolytic intermediates may interact with dopamine 
derivatives generating neurotoxins. Finally, increased glycolysis impairs antioxidant PPP. 
Thus, the compensative increase in glycolysis contributes to the cascade of events leading to 
selective degeneration of dopaminergic neurons.
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Figure 2. Metabolic shift in familial parkinsonism
Mutations in familial PD-linked genes encoding α-synuclein, parkin, DJ-1, PINK1 and 
LRRK2 are associated with PD pathogenesis. These mutations contribute to PD causing 
mitochondrial dysfunction, oxidative damage and abnormal protein aggregation and 
phosphorylation, compromising neuronal function and survival. α-Synuclein undergoes 
aggregation as a consequence of its mutation or indirectly by mutation of other PD-related 
genes, endangering protein degradation pathways and inducing ER stress and mitochondrial 
dysfunction. Mitochondrial dysfunction and oxidative damage lead to deficits in ATP, which 
activates glycolysis. This glycolytic increase can also be consequence of genetic mutations 
in Parkin, PINK1 and DJ-1, which act on specific glycolytic regulatory proteins. In addition, 
Parkin, being an E3 ubiquitin ligase, promotes proteasomal degradation, participates in 
mitochondrial fusion and fission processes, and reverses PINK1-induced mitochondrial 
dysfunction. DJ-1 protects mitochondria against oxidative stress, it functions as a 
transcriptional co-activator of PINK1, amongst others, and blocks α-synuclein aggregation. 
PINK1 protects against mitochondrial dysfunction, preventing mitochondrial ROS 
production and recruiting Parkin into mitochondria, thus controlling mitochondrial 
dynamics. LRRK2 seems to play a role in synaptic vesicles formation. LRRK2 causes 
abnormal protein phosphorylation, which induces mitochondrial-dependent cell death. 
Furthermore, familial PD-linked genes such as Parkin, PINK1, DJ-1 and α-synuclein favour 
ER-mitochondria crosstalk through maintenance of contact sites, thus promoting cell 
survivalGreen arrows indicate activating effects, and red lines with blunt ends inhibitory 
effects).
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